Previously, we have reported the 8- and 10-year outcomes of patients treated with intracoronary and intramuscular adenovirus-mediated VEGF-A injections for coronary artery disease and peripheral artery disease [8, 9]. This evidence concerns the gene VEGFA and peripheral arterial disease.